Prevention of paracentesis-induced circulatory dysfunction: Midodrine vs albumin. A randomized pilot study

Liver International

Volumn 28, Issue 7, 2008, Pages 1019-1025

  Appenrodt, Beate ^a   Wolf, Andrea ^a   Grünhage, Frank ^a   Trebicka, Jonel ^a   Schepke, Michael ^a   Rabe, Christian ^a   Lammert, Frank ^a   Sauerbruch, Tilman ^a   Heller, J ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

(Post )paracentesis induced circulatory dysfunction (PICD); Albumin; Ascites; Large volumep aracentesis; Liver cirrhosis; Midodrine

Indexed keywords

ALBUMIN; ALDOSTERONE; DIURETIC AGENT; MIDODRINE; PLACEBO; RENIN; TERLIPRESSIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTERIAL BLOOD; ARTICLE; ASCITES; BLOOD VOLUME; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; ECHOGRAPHY; FEMALE; HEMODYNAMICS; HEPATORENAL SYNDROME; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPONATREMIA; KIDNEY FUNCTION TEST; LIVER CIRRHOSIS; MALE; OUTCOME ASSESSMENT; PARACENTESIS; PARACENTESIS INDUCED CIRCULATORY DYSFUNCTION; PILOT STUDY; PLASMA RENIN ACTIVITY; POSTOPERATIVE COMPLICATION; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; TREATMENT DURATION;

ADRENERGIC ALPHA-AGONISTS; ALBUMINS; ALDOSTERONE; ASCITES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPOVOLEMIA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MIDODRINE; PARACENTESIS; PILOT PROJECTS; RENIN; TREATMENT OUTCOME;

EID: 47949091412     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2008.01734.x     Document Type: Article

References (20)

1. Gines P, Arroyo V, Quintero E, et al. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study. Gastroenterology 1987; 93: 234-41.
2. Gines P, Tito L, Arroyo V, Planas J, Vivet V, Torres M. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis. Gastroenterology 1988; 94: 1493-1502.
3. Gines A, Fernandez-Esparrach G, Monescillo A, et al. Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology 1996; 111: 1002-10.
4. Ruiz-Del-Arbol L, Monescillo A, Jimenez W, Garcia-Plaza A, Arroyo V, Rodes J. Paracentesis-induced circulatory dysfunction: Mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113: 579-86.
5. Simon DM, McCain JR, Bonkovsky HL, Wells JO, Hartle DK, Galambos JT. Effects of therapeutic paracentesis on systemic and hepatic hemodynamics and on renal and hormonal function. Hepatology 1987; 7: 423-9.
6. Planas R, Gines P, Arroyo V, et al. Dextran-70 versus albumin as plasma expanders in cirrhotic patients with tense ascites treated with total paracentesis. Results of a randomized study. Gastroenterology 1990; 99: 1736-44.
7. Salerno F, Badalamenti S, Lorenzano E, Moser P, Incerti P. Randomized comparative study of hemaccel vs albumin infusion after total paracentesis in cirrhotic patients with refractory ascites. Hepatology 1991; 13: 707-13.
8. Sola-Vera J, Minana J, Ricart E, et al. Randomized trial comparing albumin and saline in the prevention of paracentesis-induced circulatory dysfunction in cirrhotic patients with ascites. Hepatology 2003; 37: 1147-53.
9. Moreau R, Asselah T, Condat B, et al. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: A randomized pilot study. Gut 2002; 50: 90-4.
10. Singh V, Kumar R, Kanwal Nain C, Singh B, Sharma A. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: A randomized study. J Gastroenterol Hepatol 2006; 21: 303-7.
11. Angeli P, Volpin R, Gerunda G, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology 1999; 29: 1690-7.
12. Angeli P, Volpin R, Piovan D, et al. Acute effect of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotis patients with ascites. Hepatology 1998; 28: 937-43.
13. Arroyo V, Gines P, Gerbes A. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-76.
14. Mc Tavish D, Goa K. Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders. Drugs 1989; 38: 757-77.
15. Low PA, Gilden JL, Freeman R, Mc Elligott MA. Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. JAMA 1997; 277: 1046-51.
16. Alessandria C, Debernardi-Venon W, Todros L, Pizzetto M, Marzano A. Midodrine in the prevention of hepatorenal syndrome type 2 recurrence: A case-control study. J Hepatol 2007; 46(Suppl. 1): A218, S89.
17. Zanditenas D, Condat B, Blazquez M, et al. Effects of prolonged administration of midodrine in the treatment of diuretic-resistant ascites: A pilot study. J Hepatol 2007; 46(Suppl. 1): A251, S101.
18. Hennenberg M, Trebicka J, Biecker E, et al. Vascular dysfunction in human and rat cirrhosis: Role of receptor-desensitizing and calcium-sensitizing proteins. Hepatology 2007; 45: 495-506.
19. Hennenberg M, Biecker E, Trebicka J, et al. Defective RhoA/Rho-kinase signaling contributes to vascular hypocontractility and vasodilation in cirrhotic rats. Gastroenterology 2006; 130: 838-54.
20. Heller J, Schepke M, Gehnen N, et al. Altered adrenergic responsiveness of endothelium-denuded hepatic arteries and portal veins in patients with cirrhosis. Gastroenterology 1999; 116: 387-93.